Characterization of Genetically Modified HUCPVCs as an Osteogenic Cell Source.

@inproceedings{EstradaVallejo2014CharacterizationOG,
  title={Characterization of Genetically Modified HUCPVCs as an Osteogenic Cell Source.},
  author={Catalina Estrada-Vallejo},
  year={2014}
}
Tissue engineering and ex vivo gene therapy can be used synergically as tool to regenerate bone, which overcome the problems of currently available bone replacements. Recently, a new source of mesenchymal stromal cells (MSCs) has been found in the umbilical cord; human umbilical cord perivascular cells (HUCPVCs) provide an alternative to bone marrow derived MSCs and due to their easy harvest, fast expansion, and non-immunogeneic and immunomodulatory phenotype we hypothesized that HUCPVCs are a… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 308 REFERENCES

Effect of cell-based VEGF gene therapy on healing of a segmental bone defect

R Li, DJ Stewart, HP von Schroeder, ES Mackinnon, EH. Schemitsch
  • J Orthop Res
  • 2009
VIEW 20 EXCERPTS
HIGHLY INFLUENTIAL

Enhancing Production of Recombinant BMP-2 in Mammalian Cell Culture Systems by Inhibition of Pro-protein Cleavage using 9DR Peptides

Zhou J-JA
  • Jul 30 [cited
  • 2008
VIEW 17 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…